Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs Exelixis, Inc. (EXEL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | EXEL | 7.0% revenue growth vs INBX's -88.9% |
| Value | INBX | Lower P/E (0.6x vs 13.3x) |
| Quality / Margins | EXEL | 29.6% net margin vs INBX's -110.8% |
| Stability / Safety | EXEL | Beta 0.63 vs INBX's 0.74 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs EXEL's +13.9% |
| Efficiency (ROA) | EXEL | 24.0% ROA vs INBX's -87.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It generates revenue primarily from sales of its flagship drug Cabometyx — which accounts for the vast majority of its revenue — along with royalties from partnered products like Cotellic. The company's competitive advantage lies in its deep expertise in tyrosine kinase inhibitors and its focused pipeline targeting difficult-to-treat cancers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EXEL leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). INBX leads in 1 (Total Returns).
Financial Metrics (TTM)
EXEL is the larger business by revenue, generating $2.3B annually — 1634.4x INBX's $1M. EXEL is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to INBX's -110.8%.
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $2.3B |
| EBITDAEarnings before interest/tax | -$151M | $830M |
| Net IncomeAfter-tax profit | -$155M | $678M |
| Free Cash FlowCash after capex | -$143M | $753M |
| Gross MarginGross profit ÷ Revenue | -86.3% | +96.6% |
| Operating MarginEBIT ÷ Revenue | -110.0% | +35.0% |
| Net MarginNet income ÷ Revenue | -110.8% | +29.6% |
| FCF MarginFCF ÷ Revenue | -102.5% | +32.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +10.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +75.0% |
Valuation Metrics
At 0.6x trailing earnings, INBX trades at a 96% valuation discount to EXEL's 15.8x P/E.
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| Market CapShares × price | $1.1B | $11.8B |
| Enterprise ValueMkt cap + debt − cash | $930M | $11.5B |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | 15.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.29x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.31x |
| EV / EBITDAEnterprise value multiple | — | 13.19x |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | 5.09x |
| Price / BookPrice ÷ Book value/share | 8.03x | 5.75x |
| Price / FCFMarket cap ÷ FCF | — | 13.36x |
Profitability & Efficiency
EXEL delivers a 31.4% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-4 for INBX. INBX carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXEL's 0.08x. On the Piotroski fundamental quality scale (0–9), EXEL scores 7/9 vs INBX's 4/9, reflecting strong financial health.
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | +31.4% |
| ROA (TTM)Return on assets | -87.4% | +24.0% |
| ROICReturn on invested capital | — | +32.1% |
| ROCEReturn on capital employed | -169.3% | +35.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 0.08x |
| Net DebtTotal debt minus cash | -$145M | -$309M |
| Cash & Equiv.Liquid assets | $153M | $482M |
| Total DebtShort + long-term debt | $8M | $173M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | — |
Total Returns (with DRIP)
A $10,000 investment in INBX five years ago would be worth $25,954 today (with dividends reinvested), compared to $19,758 for EXEL. Over the past 12 months, INBX leads with a +459.5% total return vs EXEL's +13.9%. The 3-year compound annual growth rate (CAGR) favors INBX at 46.1% vs EXEL's 37.1% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | +1.1% |
| 1-Year ReturnPast 12 months | +459.5% | +13.9% |
| 3-Year ReturnCumulative with dividends | +211.6% | +158.0% |
| 5-Year ReturnCumulative with dividends | +159.5% | +97.6% |
| 10-Year ReturnCumulative with dividends | +263.5% | +1110.4% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +37.1% |
Risk & Volatility
EXEL is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than INBX's 0.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXEL currently trades 88.8% from its 52-week high vs INBX's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.63x |
| 52-Week HighHighest price in past year | $94.56 | $49.62 |
| 52-Week LowLowest price in past year | $10.81 | $32.38 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +88.8% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 165K | 2.1M |
Analyst Outlook
Wall Street rates INBX as "Buy" and EXEL as "Buy".
| Metric | INBXInhibrx Bioscienc… | EXELExelixis, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $44.40 |
| # AnalystsCovering analysts | 5 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +8.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| Exelixis, Inc. (EXEL) | 100 | 198.38 | +98.4% |
Inhibrx Biosciences… (INBX) returned +160% over 5 years vs Exelixis, Inc. (EXEL)'s +98%. A $10,000 investment in INBX 5 years ago would be worth $25,954 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| Exelixis, Inc. (EXEL) | $191M | $2.3B | +1111.8% |
Exelixis, Inc.'s revenue grew from $191M (2016) to $2.3B (2025) — a 31.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| Exelixis, Inc. (EXEL) | -36.7% | 33.7% | +192.0% |
Exelixis, Inc.'s net margin went from -37% (2016) to 34% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 62 | 15.8 | -74.5% |
Exelixis, Inc. has traded in a 9x–62x P/E range over 9 years; current trailing P/E is ~16x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| Exelixis, Inc. (EXEL) | -0.28 | 2.78 | +1092.9% |
Exelixis, Inc.'s EPS grew from $-0.28 (2016) to $2.78 (2025).
Chart 6Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). Exelixis, Inc. generated $884M FCF in 2025 (+163% vs 2021).
INBX vs EXEL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is INBX or EXEL a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INBX or EXEL?
On trailing P/E, Inhibrx Biosciences, Inc. (INBX) is the cheapest at 0.6x versus Exelixis, Inc. at 15.8x.
03Which is the better long-term investment — INBX or EXEL?
Over the past 5 years, Inhibrx Biosciences, Inc. (INBX) delivered a total return of +159.5%, compared to +97.6% for Exelixis, Inc. (EXEL). A $10,000 investment in INBX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: EXEL returned +1110% versus INBX's +263.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INBX or EXEL?
By beta (market sensitivity over 5 years), Exelixis, Inc. (EXEL) is the lower-risk stock at 0.63β versus Inhibrx Biosciences, Inc.'s 0.74β — meaning INBX is approximately 18% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Inhibrx Biosciences, Inc. (INBX) carries a lower debt/equity ratio of 6% versus 8% for Exelixis, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — INBX or EXEL?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus 33.7% for Exelixis, Inc. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37.6% versus -1657.2% for INBX. At the gross margin level — before operating expenses — EXEL leads at 96.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — INBX or EXEL?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is INBX or EXEL better for a retirement portfolio?
For long-horizon retirement investors, Exelixis, Inc. (EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63), +1110% 10Y return). Both have compounded well over 10 years (EXEL: +1110%, INBX: +263.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between INBX and EXEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.